Factors for Discontinuation of Naldemedine Therapy in a Palliative Ward

TAKAKI KANIE; TOMOHIRO MIZUNO; TAKENAO KOSEKI; AYA HANAMOTO; HIROKO SAWANO; MASAKO TOMIDA; YUKIKO KAKUMAE; TAKAHIRO HAYASHI; HIROSHI MATSUOKA; MASANOBU USUI; SHIGEKI YAMADA

doi:10.21873/invivo.13965

Article Information

vol. 39 no. 3 1647-1653

DOI

https://doi.org/10.21873/invivo.13965

PMID

40294999

Published By

International Institute of Anticancer Research

Print ISSN

0258-851X

Online ISSN

1791-7549

History

Received January 22, 2025
Revision received February 24, 2025
Accepted February 25, 2025
Published online April 28, 2025.

Copyright © 2025 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

TAKAKI KANIE¹,*,
TOMOHIRO MIZUNO¹ ⇑*,
TAKENAO KOSEKI¹,
AYA HANAMOTO²,
HIROKO SAWANO²,
MASAKO TOMIDA²,
YUKIKO KAKUMAE¹,
TAKAHIRO HAYASHI¹,²,
HIROSHI MATSUOKA³,
MASANOBU USUI⁴ and
SHIGEKI YAMADA¹

¹Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan;
²College of Pharmacy, Kinjo Gakuin University, Nagoya, Japan;
³Department of Surgery, Fujita Health University School of Medicine, Toyoake, Japan;
⁴Department of Palliative Medicine, Fujita Health University Hospital, Toyoake, Japan

Tomohiro Mizuno, Ph.D., Department of Pharmacotherapeutics and Informatics, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Japan. Tel: +81 562932493, Fax: +81 562934593, e-mail: tomohiro.mizuno{at}fujita-hu.ac.jp